TGTX
TG Therapeutics Inc
$7.2
Earnings Summary
Revenue | $2.02Mn |
Net Profits | $-69.01Mn |
Net Profit Margins | -3423.26% |
Highlights
TG Therapeutics Inc’s revenue jumped 154.22% since last year same period to $2.02Mn in the Q1 2022. On a quarterly growth basis, TG Therapeutics Inc has generated -13.14% fall in its revenue since last 3-months.
TG Therapeutics Inc’s net profit jumped 23.85% since last year same period to $-69.01Mn in the Q1 2022. On a quarterly growth basis, TG Therapeutics Inc has generated 26.06% jump in its net profits since last 3-months.
TG Therapeutics Inc’s net profit margin jumped 70.05% since last year same period to -3423.26% in the Q1 2022. On a quarterly growth basis, TG Therapeutics Inc has generated 14.88% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the TG Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Current Year | -0.51 |
Highlights
TG Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a 13.56% jump from last quarter’s estimates.
TG Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.51.
Key Ratios
Key ratios of the TG Therapeutics Inc post its Q1 2022 earnings
Earning Per Share (EPS) | -0.51 |
Return on Assets (ROA) | -0.43 |
Return on Equity (ROE) | -0.92 |
Dividend Per Share (DPS) | 0 |
Highlights
TG Therapeutics Inc’s earning per share (EPS) jumped 26.09% since last year same period to -0.51 in the Q1 2022. This indicates that the TG Therapeutics Inc has generated 26.09% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. TG Therapeutics Inc’s return on assets (ROA) stands at -0.43.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. TG Therapeutics Inc’s return on equity (ROE) stands at -0.92.
TG Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-10 | -0.59 | -0.51 | 13.56% |
Company Information
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.
Organisation | TG Therapeutics Inc |
Headquarters | New York, New York, US |
Employees | 272 |
Industry | Health Technology |
CEO | Michael Weiss |